Denali claims a neurofilament victory in Hunter syndrome, two years after letting down Wall Street

Max Gelman

Senior Editor

Denali Therapeutics once again touted biomarker data for its experimental Hunter syndrome drug Tuesday morning, aiming to push the program toward FDA approval after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Denali claims a neurofilament victory in Hunter syndrome, two years after letting down Wall Street

Max Gelman

Senior Editor

Sign up to read this article for free.

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Pfizer looking to sell hospital drugs unit — reports

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

De­nali claims a neu­ro­fil­a­ment vic­to­ry in Hunter syn­drome, two years af­ter let­ting down Wall Street

Max Gelman

Senior Editor

Sign up to read this article for free.

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Denali claims a neurofilament victory in Hunter syndrome, two years after letting down Wall Street

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Pfizer looking to sell hospital drugs unit — reports

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?